| Literature DB >> 30669621 |
Chengzhu Liao1, Yuchao Li2, Sie Chin Tjong3.
Abstract
Silver nanoparticles (AgNPs) can be synthesized from a variety of techniques including physical, chemical and biological routes. They have been widely used as nanomaterials for manufacturing cosmetic and healthcare products, antimicrobial textiles, wound dressings, antitumor drug carriers, etc. due to their excellent antimicrobial properties. Accordingly, AgNPs have gained access into our daily life, and the inevitable human exposure to these nanoparticles has raised concerns about their potential hazards to the environment, health, and safety in recent years. From in vitro cell cultivation tests, AgNPs have been reported to be toxic to several human cell lines including human bronchial epithelial cells, human umbilical vein endothelial cells, red blood cells, human peripheral blood mononuclear cells, immortal human keratinocytes, liver cells, etc. AgNPs induce a dose-, size- and time-dependent cytotoxicity, particularly for those with sizes ≤10 nm. Furthermore, AgNPs can cross the brain blood barrier of mice through the circulation system on the basis of in vivo animal tests. AgNPs tend to accumulate in mice organs such as liver, spleen, kidney and brain following intravenous, intraperitoneal, and intratracheal routes of administration. In this respect, AgNPs are considered a double-edged sword that can eliminate microorganisms but induce cytotoxicity in mammalian cells. This article provides a state-of-the-art review on the synthesis of AgNPs, and their applications in antimicrobial textile fabrics, food packaging films, and wound dressings. Particular attention is paid to the bactericidal activity and cytotoxic effect in mammalian cells.Entities:
Keywords: administration route; bacteria; cell culture; cytotoxicity; food packaging; membrane; polymer nanocomposite; reactive oxygen species; silver ion; wound dressing
Mesh:
Substances:
Year: 2019 PMID: 30669621 PMCID: PMC6359645 DOI: 10.3390/ijms20020449
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Figure 1Applications of AgNPs. Reproduced from [22], Springer Open.
Figure 2Uptake of AgNPs by mammalian cells (A) and by bacteria (B). (A) AgNPs can cross the plasma membrane by diffusion (1), endocytotic uptake (2,3), and disruption of membrane integrity (4). (B) AgNPs permeate the cell walls of gram-negative and gram-positive bacteria. Reproduced from [36], MDPI under the Creative Commons Attribution License.
Figure 3Schematic representation of size-controlled AgNPs synthesis employing the co-reduction strategy. Reproduced from [41], the Royal Society of Chemistry.
Figure 4TEM images of AgNPs formed at (a) pH 6, and (b) pH 12. (c) High-resolution TEM image and (d) selected area electron diffraction pattern of AgNP. Reproduced from [82] with permission of Elsevier.
Figure 5Graphical representation of AgNPs synthesis with Eucalyptus globulus leaf extract (ELE) and silver nitrate depicting scheme-I (without microwave treatment) and scheme-II with microwave irradiation. Reproduced from [106] with permission of Public Library of Science.
Figure 6Dissolved Ag+ concentration vs. air exposure time for PEG-AgNPs with sizes of 5 and 11 nm under aerobic conditions. No Ag+ ions can be detected (<1 μg/L) under anaerobic conditions. Reproduced from [147] with permission of the American Chemical Society.
Figure 7Bactericidal mechanisms of AgNPs due to their direct contact with the bacterial cell wall and the release of silver ions. Reproduced from [154] with permission of Elsevier.
Figure 8Disk diffusion assay results for AgNPs of various sizes against E. coli. The zone of inhibition is highlighted with a dashed circle indicating a noticeable antibacterial effect. Reproduced from [41], the Royal Society of Chemistry.
Figure 9Killing kinetics of K. pneumoniae AWD5 exposed to (A) spherical AgNPs at concentrations of 184–207 μg/mL and (B) rod-shaped AgNPs at 320–720 μg/mL. Results were expressed as means ± SD; n = 3. p < 0.05 was considered statistically significant. Reproduced from [161], Nature Company under the Creative Commons Attribution License.
Figure 10Assessment of antibacterial activity of ELE and ELE-AgNPs by disk diffusion assay. Reproduced from [106] with permission of Public Library of Science.
Figure 11(Left): Effect of AgNPs concentration on bacterial cell viability. Bacterial survival was determined at 24 h based on a colony-forming unit (CFU) count assay. (Right): Time-dependent bactericidal effect of AgNPs on P. aeruginosa and S. aureus. Results were expressed as means ± SD; n = 3. p < 0.05 was considered statistically significant. Reproduced from [107], MDPI under the Creative Commons Attribution License.
Figure 12Effects of AgNPs on ROS (left panel) and MDA (right panel) levels. Results were expressed as means ± SD of n = 3; p < 0.05 was considered statistically significant as compared to control (con) groups. Reproduced from [107], MDPI under the Creative Commons Attribution License.
Figure 13Anti-biofilm behavior of AgNPs on P. melaninogenica and A. pyogenes. (Left): Bacterial strains were treated with AgNPs of different concentrations. (Right): Bacterial strains were incubated with 0.8 and 1.0 μg/mL of AgNPs, respectively, for 24 h. p < 0.05 was considered statistically significant as compared to control groups. Reproduced from [38], MDPI under the Creative Commons Attribution License.
Bacterial reduction percentages of PVP-AgNP/nylon nanocomposite fabrics against E. coli and S. aureus. Reproduced from [134] with permission of Elsevier.
| Bacterium | AgNP Content (ppm) in Fabrics | Percentage of Bacterial Reduction | Number of Washing | ||
|---|---|---|---|---|---|
| 0 | 10 | 20 | 30 | ||
|
| 100 | 99.99 | 99.99 | 99.46 | 99.20 |
|
| 200 | 99.99 | 99.99 | 99.99 | 99.55 |
|
| 100 | 99.99 | 99.86 | 99.27 | 86.92 |
|
| 200 | 99.99 | 99.57 | 99.27 | 91.03 |
Figure 14Percentage of bacterial reduction (E. coli and S. aureus) as a function of the size of AgNPs after exposure of 1 day and 30 days. Data are presented as mean values ± SD (n = 3). Reproduced from [137] with permission of the American Chemical Society.
Figure 15Viable counts in the challenge test on apple peels with L. monocytogenes versus silver nitrate aqueous solution (black square), EVOH (circle), and EVOH composite films with 0.1 wt% Ag+ (diamond), 1 wt% Ag+ (square), and 10 wt% Ag+(triangle). Reproduced from [175] with permission of the American Chemical Society.
Figure 16(a) Inhibition zones of all samples exposed to S. aureus, E. coli and C. albicans. There is a significant difference between the levels indicated by arrows, * p < 0.05. (b) Cell viability of mouse fibroblasts after 24 h incubation with nanocomposite hydrogels. CVDE (cell density), NR (membrane integrity assay) and XTT (mitochondrial activity). ‘Control’ is the negative control, whereas ‘latex’ is the positive control. Reproduced from [184] with permission of the Royal Society Publishing.
Figure 17Proposed mechanisms of (a) AgNPs- and (b) silver ion-induced cytotoxicity. Reproduced from [190] and [192] with permission of BioMed Central Ltd and Elsevier, respectively.
Figure 18(A–C) Cell viability vs AgNP concentration for 16HBE, HUVECs and HepG2 cells determined from CCK-8 assay at different time points. (D) Inductively coupled plasma mass spectrometry results showing cellular uptake of AgNPs upon exposure at a dose of 2 mg/cm2 AgNPs for 24 h. Data are expressed as means ± SD, n = 5. Reproduced from [206] with permission of Elsevier.
Figure 19(A) Cell viability and (B) membrane damage of HBEC5i, HUVEC and EA.hy926 cells vs AgNPs concentrations after 24 h exposure to nanoparticles. Data are presented as means ± SD. * p < 0.05; ** p < 0.01; **** p < 0.0001. Reproduced from [59] with permission of Elsevier.
Figure 20Dose-and time-dependent ROS generation in HepG2 cells exposed to AgNPs in: (A) deionized water and (B) cell culture medium. Data are expressed as means ± SD. There was significant difference between the treated and control groups (* p < 0.05; ** p < 0.01), and between the 24- and 48-h groups (# p < 0.05). Reproduced from [194] with permission of Wiley.
Figure 21Dose-and time-dependent MMP reduction of HepG2 cells exposed to AgNPs in (A) deionized water and (B) cell culture medium. Data are expressed as means ± SD. There was significant difference between the treated and control groups (* p < 0.05; ** p < 0.01), and between the 24- and 48-h groups (# p < 0.05). Reproduced from [194] with permission of Wiley.
Figure 22(a) Schematic representation showing size-dependent hemolysis of RBCs due to AgNPs. (b) Percentage hemolysis vs AgNPs concentrations. TEM images of RBCs (c) without and (d) with AgNPs (15 nm) treatment. Individual AgNP in (d) is outlined with a red circle, while AgNPs are aggregate using black arrows. Reproduced from [213] with permission of the American Chemical Society.
Figure 23Effect of AgNPs concentration on mitochondrial metabolism (MTT assay) in murine alveolar macrophages treated with AgNPs for 24 h. The data were expressed as means ± SD (n = 3). p < 0.05 was considered significant. Reproduced from [215] with permission of the American Chemical Society.
Figure 24Cytotoxicity and IL-1β generation in PBMCs. (a) PBMCs were treated with AgNPs for 6 h and cell viability was determined with CCK-8 assay. (b) PBMCs were treated with AgNPs (5 nm) for 6 h and supernatant levels of IL-1β were assessed by ELISA. LPS (50 pg/mL) was pre-treated for 2 h before AgNPs exposure. Results were presented as means ± SD. One-way ANOVA analysis showed significance (p < 0.0001) (a,b), and Student’s t-test between certain pairs (b) was used for statistical analysis. Reproduced from [216] with permission of Elsevier.
Figure 25Correlation between cell viability and the roughness or stiffness of (A) HS-5, (B) NIH3T3 and (C) A549 cells before and after treatment with AgNPs. NP: nanoparticles; Y. M.: Young’s modulus. Reproduced from [226] with permission of Dove Medical Press Ltd.
Cytotoxic effects of AgNPs on human cell lines.
| Synthetic Route and Size | AgNPs Dosage and Exposure Time | Cell Type | Cytotoxic Effect | Ref. |
|---|---|---|---|---|
| Green & chemical reduction; 15 nm | 10, 20, 30, 40 and 50 µg/mL for 24 h | A549 | ROS creation, MMP reduction, LDH leakage, phagocytosis | [ |
| Green synthesis; 11 nm | AgNP (1 µM) + MS-275 (1 µM) for 24 h | A549 | Apoptosis due to ROS creation, LDH leakage, mitochondria dysfunction, DNA fragmentation | [ |
| Chemical reduction; 15.9 ± 7.6 nm | 12.1 µg/mL for 24 and 48 h | A549 | Exposure of AgNPs for 24 h altered the regulation of more than 1000 genes; ROS generation | [ |
| Chemical reduction; 19.5 nm | 1.25, 2.5, 5, 10, 20 and 40 µg/mL for 24 h | A549, HS-5; NIH3T3 | AgNPs treatment increased surface roughness and stiffness of the cells. | [ |
| Commercial particles; CT-AgNPs: 10, 40, 75 nm; PVP-AgNPs: 10 nm | 5, 10, 20 and 50 µg/mL for 24 h | BEAS-2B | Size-dependent toxicity. AgNPs with 10 nm were more toxic, leading to DNA damage without ROS generation | [ |
| Commercial particles; CT-AgNPs: 10, 30 and 60 nm | 10 and 40 µg/mL for 24 h and 48 h | HaCaT | Dose-dependent ROS generation | [ |
| Green synthesis; 20 nm | 10, 20, 40, 60, 80 and 100 µg/mL for 24 h | CRL-2310 | Dose-dependent toxicity. Cell viability was 98.76% at 10 µg/mL, but reduced to 74.5% at 100 µg/mL | [ |
| Commercial particles; Pristine AgNPs: 42 nm; PEI/PVP coated-AgNPs: 4.7 nm | AgNPs: 0.1, 0.5, 1.6 and 6.7 µg/mL. | HPF and NDHF | DNA strand breaks in a dose- and time-dependent manner. Smaller coated-AgNPs were more genotoxic than larger pristine AgNPs | [ |
| Chemical reduction; 65 nm | 0.5, 1, 1.5 and 2 µg/mL | HUVEC | Dose-dependent toxicity. ROS creation and cell dysfunction via IKK/NF-κB pathways | [ |
| Commercial particles; <100 nm | 5, 10, 15, 25, 35, 40 and 50 µg/mL for 24 h | HBEC5i; HUVEC; EA.hy926 | Cell viability and membrane damage were dose-dependent. | [ |
| Commercial particles; 15 nm | 40, 80 and 160 µg/mL for 24 h and 48 h | HepG2 | Dose-dependent cytotoxicity. ROS creation, MPP reduction & apoptosis | [ |
| Green synthesis; 10–50 nm | 1, 5, 10, 20, 40 and 80 µg/mL for 24 h | HepG2 | Dose-dependent cytotoxicity; IC50 = 20 µg/mL | [ |
| Commercial particles; 60 nm | 10, 20 and 40 µg/mL for 24 h | HEK293T | Decreased cell viability, increased DNA damage by exposing to AgNPs with increasing concentration | [ |
| Chemical reduction; | 100, 200, 300, 400 and 500 µg/mL for 2 h | Human erythrocyte | Size- and dose- dependent hemolysis | [ |
| Commercial particles; 5, 28 and 100 nm | 0.15, 3, 6, 9, 1.15, 1.25, 2.5 and 6.25 µg/mL for 6 h | PBMC | Dose-dependent cytotoxicity. AgNPs induced inflammasomes to produce IL-1β. | [ |
| Green synthesis; 24.4 nm | 2, 5, 6.25, 10, 12.5, 50 µg/mL for 24 h | THP-1 | Cell death more than 42% at 12.5 µg/mL AgNPs. Induced cytokines IL-6 and TNF-α | [ |
| Commercial particles; 10, 20, 50 and 100 nm | 1, 2.5, 5, 10, 15 and 25 µg/mL for 24 h | THP-1 | AgNPs (10 nm) and AgNPs (20 nm) induced DNA damage | [ |
| Chemical reduction; 23 nm | 1, 5, 10, 20 µg/mL for 24 h | NSC | Reduction in mitochondrial metabolism; increased LDH leakage and ROS level | [ |
Figure 26Histological examination of silver tissue localization by autometallography staining. Representative images of spleen, liver, kidney, and lung (scale bar = 20 μm), from AgNPs (10, 40, 100 nm) and silver acetate treated mice. In the spleen, silver was localized within the cytoplasm of macrophages especially in the spleen white pulp (WP) and red pulp (RP). Triangles indicate the accumulation of silver in organ tissues. Reproduced from [229], BioMed Central Ltd under the Creative Commons Attribution License.
Figure 27Silver tissue concentration after i.v. injection of AgNPs and AgAc in mice. Data are expressed as means ± SD. The inset illustrates a magnified view showing Ag concentration in the kidney, brain, and blood. Statistical significance: a = p < 0.05; b = p < 0.01. Reproduced from [229], BioMed Central Ltd under the Creative Commons Attribution License.
Figure 28Silver concentrations in major organs and plasma of (A) male and (B) female rats. Values are presented as means ± SD, n = 5. The asterisk (*) indicates significant difference between AgNPs and AgNO3 treatment groups at p < 0.05. Means with the same capital letters are not significantly different among AgNPs groups (p < 0.05) and same small letter are not statistically different among AgNO3 groups by the Tukey test (p < 0.05). Reproduced from [238] with permission of Wiley.
Recent in vivo studies showing biodistribution and toxicity of AgNPs in rodents through different administration routes.
| Coating Type & Size of AgNPs | Model | Dosage & Exposure Time | Entry Route | Cytotoxic Effect | Ref. |
|---|---|---|---|---|---|
| CT and PVP; 10, 40 &100 nm | CD-1 Mice | 10 mg/kg bw;24 h |
| Biodistributed in spleen and liver followed by lung, kidney and brain. AgNPs (10 nm) are the most toxic nanoparticles | [ |
| Carboxyl; 3 nm | KM Mice | 11.3–13.3 mg/kg bw; 4 weeks |
| Biodistributed mainly in spleen and liver, followed by kidney, lung, heart and testis | [ |
| CT; 6.3 nm | SD rats | 5 mg/kg bw; 24 h |
| Biodistributed in the organs with decreasing Ag concentration, i.e., lung > spleen > liver > kidney > thymus > heart | [ |
| PVP; 26.2 nm | SD rats | 0.1 and 1 mg/kg bw per day for 4 and 12 weeks | Intranasal instillation | Dose- and time-dependent accumulation of both AgNPs and silver ion (AgNO3) in liver, lung and brain | [ |
| 2 and 20 nm | Wistar rats | 5 mg/kg bw; 1, 7and 28 days |
| Time- and size-dependent accumulation of AgNPs in the liver, spleen, kidney and brain | [ |
| PVP; 10–30 nm | SD rats | 500 mg/kg bw; 1, 4, 7, 10 and 30 days |
| AgNPs located mainly in the liver. A significant increase in caspase-3 in the liver of treated rats from day 1 to day 30 | [ |
| CT; 3–10 nm | SD rats | 1mg/kg bw. and 10 mg/kg bw for 14 days | Intragastric | Neuron shrinkage, cytoplasmic or foot swelling of astrocytes and inflammation | [ |
| CT; 10 nm | Wistar rats | 0.2 mg/kg bw per day for 14 days | Gastro-intestinal | Enhanced lipid peroxidation and decreased concentrations of protein and non-protein –SH groups in myelin | [ |
| CT, PVP; 20 and 110 nm | Black 6 mice | 0.1, 1, 100 mg/kg bw per day for 3 days | Oral gavage | No toxicity and no significant tissue accumulation | [ |
| CT; 10, 75 & 110 nm | SD rats | 9, 18, 36 mg/kg bw for 13 weeks | Oral gavage | AgNPs predominantly deposited within cells of major organs | [ |
| PVP; 28–43 nm | SD rats | 0.5 and 1 mg/kg bw daily for 28 days | Oral admi-nistration | Biodistributed in liver, kidney, spleen and blood plasma. | [ |
| CT, PVP; 20 and 110 nm | SD rats | 0.5 and 1 mg/kg bw for 1, 7 and 21 days | CT-AgNPs persisted in the lung to 21 days with retention >90%, while PVP-AgNP had lower retention of less than 30%. CT-AgNPs triggered lung macrophages for clearance of AgNPs | [ |